Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 304

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 304
---
 of a Qualifying
IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective
loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares
during the first five trading days following the consummation of such initial public offering. As of January 15, 2025, the Company received
$250,000 under such Bridge Loans.

Between December 2023 and
January 2024, we entered into the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate amount of $150,000 from
the lenders thereto including certain related parties. In October 2024, we amended the 2024 Loan Agreements pursuant to which the 2024
Loan Agreements have been extended until August 31, 2025 and shall bear interest at 8% per annum until maturity commencing as of September
1, 2024. Furthermore, upon the occurrence of a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase
such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share
equal to 75% of the lowest price per share of the Ordinary Shares during the first five trading days following the consummation of such
initial public offering.

The sales of the above securities
were deemed to be exempt from registration under the Securities Act because they were made outside of the United States of America to
certain non-U.S. individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under
Section 4(a)(2) of the Securities Act and the regulations promulgated thereunder.

We claimed exemption from
registration under the Securities Act for the option grants described above under Section 4(a)(2), Regulation S, or under Rule 701
of the Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation.

No underwriters were employed
in connection with the securities issuances set forth in this Item.

<div align='center'>II-3</div>

Item 8. Exhibits and Financial Statement Schedules.

(a) Exhibits. See the Exhibit Index attached
to this registration statement, which is incorporated by reference herein.

(b) Financial Statement Schedules. Schedules
not listed above have been omitted because the information